Targeted screening could hugely improve the chances for lung cancers to be picked up early enough to be cured. Yet lung cancer screening remains a low priority in Europe. Janet Fricker looks at the evidence supporting screening, and at the questions regions and countries need to address to develop screening programmes that work for their populations and health systems.

Evidence-based medicine is the cornerstone of medical practice, and yet clinicians are rarely offered training in the tricky business of finding, evaluating and making sense of the evidence they need. Anna Rouillard reports on an ESO-Cochrane Masterclass which seeks to fill that gap.

Over the past forty years, adult acute lymphoblastic leukaemia (ALL) has moved from heavy “one-size-fits-all” chemotherapy to highly tailored, biology-driven care. In the early 1980s, Dieter Hoelzer’s landmark multicentre trial in Germany applied paediatric-inspired combinations – vincristine, prednisone, daunorubicin, asparaginase, cytarabine and 6-mercaptopurine – raising complete remission rates to nearly 78% but still grappling with severe toxicity and frequent relapse.